Search

Take a look at the one-year chart for Pharmacopeia Drug Discovery Inc.'s stock, and you'll see a steady climb upward with a particular spike recently, when the firm entered a [...]

Biotech companies, heavy with PhDs studying the safety and efficacy of experimental compounds, would do well to balance the same two factors in their financing instruments, said Brendan Dyson, who [...]

Last week's potential $840 million deal garnered by Trubion Pharmaceuticals Inc. from Wyeth Pharmaceuticals Inc. drew attention not only to big pharma's abiding interest in the 'right' platform but to [...]

Hope for the expanding arsenal of drugs against HIV continued to grow last week with news of Tanox Inc.'s favorable Phase II data from an ongoing trial with TNX-355, the [...]

'We think, unquestionably, we're the leaders,' said Van Miles, senior vice president of business development for Alnylam Pharmaceuticals Inc., talking last week about RNA interference. Howard Robin, CEO of Sirna [...]

Shortly before Christmas last year, when Serono SA signed a potential $290 million deal with CancerVax Corp., the drug at the center of the agreement--lead product Canvaxin, a Phase III [...]

The trouble started in mid-October. That's when the price of Amgen Inc.'s shares, which had been at about $67, fell like autumn leaves, dipping just below $62 before an upsurge [...]

As a bridge over troubled financing waters, Small Business Innovation Research grants have an indisputable value, and the advantages are especially well known to start-up biotechnology companies that have availed [...]

Last week's news of a planned $600 million cash buyout of SangStat Medical Corp. by Genzyme Corp. made headlines for its obvious virtues on both sides--but down the road an [...]

Genentech Inc., called the 'premier' biotechnology firm by Elise Wang, analyst with Salomon Smith Barney -- and Wang is hardly alone in her opinion -- stands as one of the [...]

Talk about a hard call. Investors may have been quick to attach their unmistakable meaning to last month's disclosure by VaxGen Inc. of disappointing Phase Ill results for its HIV [...]

LSD, still best known as the acronym for the once-popular hippie drug lysergic acid diethylamide, also is recognized to stand for something else in the pharmaceutical world. And that something [...]

During the 1960s, labels of any kind were abhorred by many for the way they so fixedly identified objects and people, limiting them to a static condition that idealistic New [...]

With both sides still out for blood in the battle over their respective anti-anemia erythropoietin products. Transkaryotic Therapies Inc. (which won European approval in March for Dynepo) and Amgen Inc. [...]

The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against stage IV metastatic breast cancer was enough to feed another round [...]

SAN FRANCISCO -- Talk about a hard act to follow. After 2000's boom, which brought about a nearly hysterical financial ride for the Industry, almost anything would have looked worse. [...]

The decision last week by Novo Nordisk AS to drop its Phase III inhaled-insulin program mildly stung licensor Aradigm Corp., putting observers in mind of Pfizer Inc.'s dump of Exubera [...]

When Pfizer Inc. won U.S. approval of its alpha-2 delta ligand Lyrica, people with fibromyalgia syndrome (FMS) gained their first official therapy for the painful, head-to-toe disorder, which brings a [...]

Goodbye, 2007: The year finished with a splutter of moderately bad, or somewhat good, or just plain confusing news from a handful of well-known players in the cancer space. December's [...]

Remember FDA-stalled oritavancin? The hospital-based glycopeptide antibiotic acquired in 2001 by InterMune Inc. from Eli Lilly and Co. (which developed the compound as a replacement for vancomycin, which still takes [...]

Among drugs for the consequences of chemo, those with the highest profile are Amgen Inc.'s erythropoietin stimulating agents, Epogen (epoetin alfa) and Aranesp (darbepoetin alfa), and Ortho Biotech Products LP's [...]

The FDA's stance on generics -- at least on versions of the blood thinner Lovenox, such as Momenta Pharmaceuticals Inc.'s M-Enoxaparin (and probably similar compounds from Teva Pharmaceuticals Industries Ltd. [...]

Genelabs Technologies Inc.'s $23.7 million financing at the start of October sparked renewed interest in its Phase III drug Prestara for lupus - and in the indication itself, for which [...]

The phrase 'rheumatoid arthritis' almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). Partnered for marketing with Biogen Idec [...]

As a therapeutic indication, rheumatoid arthritis gets more love from investors, but another painful joint disorder has come to the fore as well, and Savient Pharmaceuticals Inc. is the company [...]

SAN FRANCISCO -- Remember Zevalin? The oncetrumpeted radioactive immune therapy for non-Hodgkin's lymphoma from IDEC Pharmaceuticals Inc. (now Biogen Idec Inc.) won approval in February 2002. Hopes ran high, with [...]

Nothing was more in the news of biotech during the past week than hepatitis C virus. Thanks to setbacks and blowups with drug candidates, HCV has taken plenty of headline [...]

Insomnia made headlines last month by way of a company takeover, the purchase of drug rights in Europe, and mixed but intriguing Phase II results with a much-needed, potential new [...]

Topping last week's news: Outcomes for ImClone Systems Inc. with its Erbitux for cancer, and Amgen Inc.'s ambivalently received results from an FDA panel meeting related to anemia products, also [...]

Last week's new deal between Aradigm Corp. and existing partner United Therapeutics Corp. - through its wholly owned subsidiary Lung Rx Inc. - to develop Remodulin (treprostinil) using the former's [...]

As one of the latest efforts to stir the stagnated migraine market - Pozen Inc.'s combination therapy Trexima, which pairs sumatriptan with the non-steroidal anti-inflammatory drug naproxen - continues to [...]

July's death of a patient in Targeted Genetics Inc.'s halted Phase I/II trial of the arthritis drug tgAAC94 shone the spotlight--unfavorably, again--on gene therapy, dragging all involved companies out for [...]

As Amgen Inc. gears up for its legal skirmish over Mircera, the erythropoietin stimulating agent (ESA) from F. Hoffmann-La Roche Ltd., the Centers for Medicare & Medicaid Services last week [...]

Investor jitters eased somewhat as the Centers for Medicare & Medicaid Services' plans for reimbursement of erythropoietin (EPO) stimulating agents (ESAs) became clearer, and backers of Amgen Inc. found cause [...]

Pfizer Inc.'s approval by the FDA of Lyrica (pregabalin) for fibromyalgia turned more investor eyes to Cypress Bioscience Inc., which lately reaped the benefits of positive Phase III news with [...]

Finding a drug that can re-educate the body's confusion in lupus has proven a puzzler for biotech firms for years, and opinion is divided on which companies might be getting [...]

Onyx Pharmaceuticals Inc. and partner Bayer Healthcare Pharmaceuticals Inc. stole the show at this year's American Society of Clinical Oncology meeting with results from the Phase III trial with Nexavar [...]

Figuring out the pulmonary arterial hypertension race is like betting on horses, but a trio of leading PAH doctors who dined with C.E. Unterberg, Towbin in San Francisco earlier this [...]

Amgen Inc.'s second infusion of bad news last week for its briskly selling erythropoietin products sent analysts to their drawing boards and crystal balls, trying to gauge the impact for [...]

Non-small-cell lung cancer gets most of the press, but the less common, small-cell tumors strike in about 25 percent of cases--and could provide an entry to the market followed by [...]

Though more than 10 years old, the concept of 'disruptive technology' holds strong appeal, and in biotech vascular disrupting agents (VDAs) occupy a rising-star approach first discovered even longer ago. [...]

Maybe AstraZeneca plc's top-heavy payout of $15.2 billion for MedImmune Inc. doesn't entirely change the way biotech firms are valued, but the deal made public last week is enough to [...]

New Phase II data from a combination trial disclosed last week for Telcyta at the American Association for Cancer Research's annual meeting spelled relief for some of Telik Inc.'s investors, [...]

The mid-game turnaround late last month by FDA panel members considering Dendreon Corp.'s cancer immunotherapy Provenge (sipuleucel T) has armchair bookies debating chances for approval by the May 15 PDUFA [...]

The FDA's blessing of Cephalon Inc.'s sleepiness drug Nuvigil came right on time, but brought a demand for boldface label warnings about skin rash--and didn't do much to soothe investors [...]

At the start of the month, Pharmion Corp. said the European Medicines Agency accepted for review its application for Thalidomide Pharmion, its therapy for untreated multiple myeloma that was licensed [...]

Investors cheered over Human Genome Sciences Inc.'s Phase IIb news about two weeks ago that Albuferon worked when given at 900-mcg doses every two weeks with ribavarin to genotype 1, [...]

Glufosfamide's Phase III fizzle in second-line pancreatic cancer pared away almost 60 percent of Threshold Pharmaceuticals Inc.'s value last week and put a dent in hopes raised by Phase II [...]